UBT251, a novel triple GLP-1, GIP, and glucagon receptor agonist, in adults with overweight or obesity: A multicenter, randomized phase 2 trial.

UBT251 achieved up to 19.7% weight loss in adults with overweight or obesity over 24 weeks, significantly surpassing placebo effects in a phase 2 trial.

• Why it matters: Effective weight management therapies are limited, and novel treatments targeting multiple metabolic pathways could improve outcomes and reduce cardiometabolic risks.
• What they did: Researchers conducted a multicenter, randomized, double-blind, placebo-controlled trial with 205 adults receiving weekly doses of UBT251 at varying levels, assessing body weight and metabolic parameters over 24 weeks.
• The result: UBT251 led to substantial weight loss, improved cardiometabolic markers, and had an acceptable safety profile, supporting further evaluation in phase 3 studies.